Antibody-Dependent Cell-Mediated Cytotoxicity to Hemagglutinin of Influenza A Viruses After Influenza Vaccination in Humans

Overview

Journal Open Forum Infect Dis

Specialty Infectious Diseases

Date 2016 Jul 16

PMID 27419174

Citations 14

Authors

Weimin Zhong

Feng Liu

Jason R Wilson

Crystal Holiday

Zhu-Nan Li

Yaohui Bai

Wen-Pin Tzeng

James Stevens

Ian A York

Min Z Levine

Affiliations

Soon will be listed here.

Abstract

Background. Detection of neutralizing antibodies (nAbs) to influenza A virus hemagglutinin (HA) antigens by conventional serological assays is currently the main immune correlate of protection for influenza vaccines However, current prepandemic avian influenza vaccines are poorly immunogenic in inducing nAbs despite considerable protection conferred. Recent studies show that Ab-dependent cell-mediated cytotoxicity (ADCC) to HA antigens are readily detectable in the sera of healthy individuals and patients with influenza infection. Methods. Virus neutralization and ADCC activities of serum samples from individuals who received either seasonal or a stock-piled H5N1 avian influenza vaccine were evaluated by hemagglutination inhibition assay, microneutralization assay, and an improved ADCC natural killer (NK) cell activation assay. Results. Immunization with inactivated seasonal influenza vaccine led to strong expansion of both nAbs and ADCC-mediating antibodies (adccAbs) to H3 antigen of the vaccine virus in 24 postvaccination human sera. In sharp contrast, 18 individuals vaccinated with the adjuvanted H5N1 avian influenza vaccine mounted H5-specific antibodies with strong ADCC activities despite moderate virus neutralization capacity. Strength of HA-specific ADCC activities is largely associated with the titers of HA-binding antibodies and not with the fine antigenic specificity of anti-HA nAbs. Conclusions. Detection of both nAbs and adccAbs may better reflect protective capacity of HA-specific antibodies induced by avian influenza vaccines.

Citing Articles

Antibody-mediated NK cell activation as a correlate of immunity against influenza infection.

Boudreau C, Burke 4th J, Yousif A, Sangesland M, Jastrzebski S, Verschoor C Nat Commun. 2023; 14(1):5170.

PMID: 37620306 PMC: 10449820. DOI: 10.1038/s41467-023-40699-8.

Influenza A(H7N9) Pandemic Preparedness: Assessment of the Breadth of Heterologous Antibody Responses to Emerging Viruses from Multiple Pre-Pandemic Vaccines and Population Immunity.

Levine M, Holiday C, Bai Y, Zhong W, Liu F, Jefferson S Vaccines (Basel). 2022; 10(11).

PMID: 36366364 PMC: 9694415. DOI: 10.3390/vaccines10111856.

Development of antibody-dependent cellular cytotoxicity in response to recombinant and live-attenuated herpes zoster vaccines.

Park S, Levin M, Canniff J, Johnson M, Schmid D, Weinberg A NPJ Vaccines. 2022; 7(1):123.

PMID: 36284110 PMC: 9593992. DOI: 10.1038/s41541-022-00545-2.

Antibody Focusing to Conserved Sites of Vulnerability: The Immunological Pathways for 'Universal' Influenza Vaccines.

Sangesland M, Lingwood D Vaccines (Basel). 2021; 9(2).

PMID: 33562627 PMC: 7914524. DOI: 10.3390/vaccines9020125.

Influenza A Virus Antibodies with Antibody-Dependent Cellular Cytotoxicity Function.

Gao R, Sheng Z, Sreenivasan C, Wang D, Li F Viruses. 2020; 12(3).

PMID: 32121563 PMC: 7150983. DOI: 10.3390/v12030276.

References

Lipatov A, Hoffmann E, Salomon R, Yen H, Webster R . Cross-protectiveness and immunogenicity of influenza A/Duck/Singapore/3/97(H5) vaccines against infection with A/Vietnam/1203/04(H5N1) virus in ferrets. J Infect Dis. 2006; 194(8):1040-3. DOI: 10.1086/507709. View

Khurana S, Loving C, Manischewitz J, King L, Gauger P, Henningson J . Vaccine-induced anti-HA2 antibodies promote virus fusion and enhance influenza virus respiratory disease. Sci Transl Med. 2013; 5(200):200ra114. DOI: 10.1126/scitranslmed.3006366. View

Wilson I, Cox N . Structural basis of immune recognition of influenza virus hemagglutinin. Annu Rev Immunol. 1990; 8:737-71. DOI: 10.1146/annurev.iy.08.040190.003513. View

GERHARD W, Yewdell J, Frankel M, Webster R . Antigenic structure of influenza virus haemagglutinin defined by hybridoma antibodies. Nature. 1981; 290(5808):713-7. DOI: 10.1038/290713a0. View

Li Z, Carney P, Lin S, Li J, Chang J, Veguilla V . Improved specificity and reduced subtype cross-reactivity for antibody detection by ELISA using globular head domain recombinant hemagglutinin. J Virol Methods. 2014; 209:121-5. DOI: 10.1016/j.jviromet.2014.09.006. View

Monsalvo A, Batalle J, Lopez M, Krause J, Klemenc J, Hernandez J . Severe pandemic 2009 H1N1 influenza disease due to pathogenic immune complexes. Nat Med. 2010; 17(2):195-9. PMC: 3034774. DOI: 10.1038/nm.2262. View

Cox R, Madhun A, Hauge S, Sjursen H, Major D, Kuhne M . A phase I clinical trial of a PER.C6 cell grown influenza H7 virus vaccine. Vaccine. 2009; 27(13):1889-97. DOI: 10.1016/j.vaccine.2009.01.116. View

Jegaskanda S, Job E, Kramski M, Laurie K, Isitman G, De Rose R . Cross-reactive influenza-specific antibody-dependent cellular cytotoxicity antibodies in the absence of neutralizing antibodies. J Immunol. 2013; 190(4):1837-48. DOI: 10.4049/jimmunol.1201574. View

Co M, Terajima M, Thomas S, Jarman R, Rungrojcharoenkit K, Fernandez S . Relationship of preexisting influenza hemagglutination inhibition, complement-dependent lytic, and antibody-dependent cellular cytotoxicity antibodies to the development of clinical illness in a prospective study of A(H1N1)pdm09 Influenza in children. Viral Immunol. 2014; 27(8):375-82. PMC: 4183906. DOI: 10.1089/vim.2014.0061. View

10.

DiLillo D, Tan G, Palese P, Ravetch J . Broadly neutralizing hemagglutinin stalk-specific antibodies require FcγR interactions for protection against influenza virus in vivo. Nat Med. 2014; 20(2):143-51. PMC: 3966466. DOI: 10.1038/nm.3443. View

11.

Jegaskanda S, Laurie K, Amarasena T, Winnall W, Kramski M, De Rose R . Age-associated cross-reactive antibody-dependent cellular cytotoxicity toward 2009 pandemic influenza A virus subtype H1N1. J Infect Dis. 2013; 208(7):1051-61. DOI: 10.1093/infdis/jit294. View

12.

Wilson J, Guo Z, Tzeng W, Garten R, Xiyan X, Blanchard E . Diverse antigenic site targeting of influenza hemagglutinin in the murine antibody recall response to A(H1N1)pdm09 virus. Virology. 2015; 485:252-62. PMC: 5737639. DOI: 10.1016/j.virol.2015.08.004. View

13.

Mozdzanowska K, Feng J, Gerhard W . Virus-neutralizing activity mediated by the Fab fragment of a hemagglutinin-specific antibody is sufficient for the resolution of influenza virus infection in SCID mice. J Virol. 2003; 77(15):8322-8. PMC: 165237. DOI: 10.1128/jvi.77.15.8322-8328.2003. View

14.

Zakay-Rones Z . Human influenza vaccines and assessment of immunogenicity. Expert Rev Vaccines. 2010; 9(12):1423-39. DOI: 10.1586/erv.10.144. View

15.

Ellebedy A, Ducatez M, Duan S, Stigger-Rosser E, Rubrum A, Govorkova E . Impact of prior seasonal influenza vaccination and infection on pandemic A (H1N1) influenza virus replication in ferrets. Vaccine. 2010; 29(17):3335-9. PMC: 3026885. DOI: 10.1016/j.vaccine.2010.08.067. View

16.

Jackson L, Campbell J, Frey S, Edwards K, Keitel W, Kotloff K . Effect of Varying Doses of a Monovalent H7N9 Influenza Vaccine With and Without AS03 and MF59 Adjuvants on Immune Response: A Randomized Clinical Trial. JAMA. 2015; 314(3):237-46. DOI: 10.1001/jama.2015.7916. View

17.

Binyamin L, Alpaugh R, Hughes T, Lutz C, Campbell K, Weiner L . Blocking NK cell inhibitory self-recognition promotes antibody-dependent cellular cytotoxicity in a model of anti-lymphoma therapy. J Immunol. 2008; 180(9):6392-401. PMC: 2810560. DOI: 10.4049/jimmunol.180.9.6392. View

18.

Endo A, Itamura S, Iinuma H, Funahashi S, Shida H, Koide F . Homotypic and heterotypic protection against influenza virus infection in mice by recombinant vaccinia virus expressing the haemagglutinin or nucleoprotein of influenza virus. J Gen Virol. 1991; 72 ( Pt 3):699-703. DOI: 10.1099/0022-1317-72-3-699. View

19.

Mulligan M, Bernstein D, Winokur P, Rupp R, Anderson E, Rouphael N . Serological responses to an avian influenza A/H7N9 vaccine mixed at the point-of-use with MF59 adjuvant: a randomized clinical trial. JAMA. 2014; 312(14):1409-19. DOI: 10.1001/jama.2014.12854. View

20.

Impagliazzo A, Milder F, Kuipers H, Wagner M, Zhu X, Hoffman R . A stable trimeric influenza hemagglutinin stem as a broadly protective immunogen. Science. 2015; 349(6254):1301-6. DOI: 10.1126/science.aac7263. View